RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
9 Meters Biopharma Stock

9 Meters Biopharma P/S 2024

9 Meters Biopharma P/S

0

Ticker

NMTR

ISIN

US6544051096

WKN

A2P362

As of Nov 17, 2024, 9 Meters Biopharma's P/S ratio stood at 0, a 0% change from the 1.44 P/S ratio recorded in the previous year.

The 9 Meters Biopharma P/S history

9 Meters Biopharma Aktienanalyse

What does 9 Meters Biopharma do?

9 Meters Biopharma Inc is a company that specializes in researching, developing, and marketing innovative therapeutic treatment options for various chronic diseases. Founded in 2010, the company has since become a major player in the biopharmaceutical drug development industry. The main goal of 9 Meters Biopharma is to provide new and effective treatment options to patients suffering from chronic diseases. The company focuses on the areas of gastroenterology, oncology, autoimmune diseases, and rare diseases. Its business model is based on identifying promising drug candidates and conducting clinical trials to prove the effectiveness and safety of the drugs. Once a drug is successfully developed, the company focuses on marketing and distributing the medication. One of the company's key products is the drug NMIL1701, which is developed for the treatment of patients with celiac disease. The medication targets the breakdown of gluten, which is present in many foods and can cause an inappropriate immune response and chronic inflammation in the intestines of people with celiac disease. Additionally, the company is currently developing medications for the treatment of ulcerative colitis, Crohn's disease, and pancreatitis. It is also researching the development of drugs for the treatment of various cancers and autoimmune diseases, including multiple sclerosis, lupus, and rheumatoid arthritis. Another important aspect of 9 Meters Biopharma's activities is collaborating with other companies and organizations to accelerate and improve drug development. The company works with various academic institutions and research organizations to jointly work on the development of new therapies. Overall, 9 Meters Biopharma Inc has established itself as a dynamic and innovative company in the biopharmaceutical landscape. With its strong focus on the development of novel therapies and collaboration with other organizations, the company is likely to continue playing a major role in improving healthcare and treating chronic diseases. 9 Meters Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding 9 Meters Biopharma's P/S Ratio

9 Meters Biopharma's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing 9 Meters Biopharma's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating 9 Meters Biopharma's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in 9 Meters Biopharma’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about 9 Meters Biopharma stock

What is the price-to-earnings ratio of 9 Meters Biopharma?

The price-earnings ratio of 9 Meters Biopharma is currently 0.

How has the price-earnings ratio of 9 Meters Biopharma changed compared to last year?

The price-to-earnings ratio of 9 Meters Biopharma has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of 9 Meters Biopharma high compared to other companies?

Yes, the price-to-earnings ratio of 9 Meters Biopharma is high compared to other companies.

How does an increase in the price-earnings ratio of 9 Meters Biopharma affect the company?

An increase in the price-earnings ratio of 9 Meters Biopharma would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of 9 Meters Biopharma affect the company?

A decrease in the price-earnings ratio of 9 Meters Biopharma would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of 9 Meters Biopharma?

Some factors that influence the price-earnings ratio of 9 Meters Biopharma are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does 9 Meters Biopharma pay?

Over the past 12 months, 9 Meters Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, 9 Meters Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of 9 Meters Biopharma?

The current dividend yield of 9 Meters Biopharma is .

When does 9 Meters Biopharma pay dividends?

9 Meters Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of 9 Meters Biopharma?

9 Meters Biopharma paid dividends every year for the past 0 years.

What is the dividend of 9 Meters Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is 9 Meters Biopharma located?

9 Meters Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von 9 Meters Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of 9 Meters Biopharma from 11/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did 9 Meters Biopharma pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of 9 Meters Biopharma in the year 2023?

In the year 2023, 9 Meters Biopharma distributed 0 USD as dividends.

In which currency does 9 Meters Biopharma pay out the dividend?

The dividends of 9 Meters Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von 9 Meters Biopharma

Our stock analysis for 9 Meters Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of 9 Meters Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.